

Meningococcal Vaccines Work Group Update

Lorry Rubin, M.D.
Chair, Meningococcal Work Group
Advisory Committee on Immunization Practices
October 21, 2015

Work Group Members

ACIP Members

Lorry Rubin (Chair)
Kathleen Harriman
Lee Harrison
David Stephens

***Ex Officio* Members**

Lucia Lee (FDA)
Anuja Rastogi (FDA)

CDC Work Group Lead

Jessica MacNeil (CDC/NCIRD)

Liaison and Other Representatives

Susan Even (ACHA)
Rachel Herlihy (IAC)
Nneka Holder (SAHM)
Martin Luta (CSTE)
Ruth Lynfield (AAP)
Jeffrey Moore (AAFP)
William Schaffner (NFID)
Margaret Yacovone (DOD)
Bill Atkinson
Carol Baker
Mike Brady
Doug Campos-Outcalt
Richard Clover
Mary Healy
Scott Kapoor
Paul McKinney
Cody Meissner
Paul Offit
Georges Peter

ACIP Recommendation: Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults, June 2015

- A serogroup B meningococcal (MenB) vaccine series may be administered to adolescents and young adults 16 through 23 years of age to provide short term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16 through 18 years of age. (Category B)**

ACIP Meningococcal Vaccine Work Group Activities

- ❑ **Policy Note: Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults, Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015**
 - To be published in MMWR on October 23, 2015

Challenges when Considering Routine Use of MenB Vaccines in Adolescents

- ❑ **Proportion of serogroup B cases that could be prevented with MenB vaccines is unknown**
 - Breadth of strain coverage estimated; actual breadth of strain coverage unclear
 - Available antibody persistence data suggests limited duration of protection
- ❑ **Effectiveness data are not available**
 - Licensure is based on bactericidal activity
 - Universal programs not implemented in any country to date
- ❑ **Impact on carriage unknown**
- ❑ **Potential impact of vaccine pressure on circulating strains unknown**

Additional Data for MenB Vaccines Reviewed by Work Group Since June 2015

- ❑ **Preliminary safety and immunogenicity data from two phase 3 studies for MenB-FHbp**
 - Includes immunogenicity data on 10 secondary strains
 - Pfizer to present data to ACIP in February 2016
- ❑ **Safety summary from CDC Immunization Safety Office (as of October 5, 2015)**

Safety Monitoring

- ❑ **Vaccine Adverse Event Reporting System (VAERS)**
 - Few reports received as of 10/05/2015
 - MenB-FHbp n=65
 - MenB-4C n=21
 - No safety signals detected to date
- ❑ **Vaccine Safety Datalink (VSD)**
 - Few doses administered in the VSD population to date
 - Safety assessment can begin when a larger number of doses have accumulated

Meningococcal Outbreak Work Group

- ❑ **Ad hoc work group comprised of ACIP Meningococcal Work Group members, ACIP members, state public health officials, college health professionals, and CDC**
 - Re-convened September 3, 2015 with biweekly meetings
- ❑ **Objectives:**
 - Review available data on the recent epidemiology of meningococcal disease and outbreaks
 - Review safety and immunogenicity of meningococcal vaccines
 - Update and harmonize the current meningococcal outbreak guidelines for serogroups ABCWY

Deliverables

- ❑ **Meningococcal Outbreak Work Group recommendations will be presented in an informational session at ACIP**
 - February 2016 or June 2016
- ❑ **Harmonized outbreak guidelines will be published in MMWR**

Today's Session

- ❑ **Serogroup C Outbreak among Men Who Have Sex With Men (MSM), Chicago, 2015**
 - Dr. Sarah Kemble, Chicago Department of Public Health

Future Work Group Activities

- **Re-evaluate policy options for use of meningococcal conjugate (MenACWY) in MSM or HIV-infected MSM**
 - Review prior ACIP discussions (February 2014)
 - Evaluate recent data on outbreaks of serogroup C meningococcal disease occurring in MSM, and sporadic cases
 - Including results of an analysis to estimate risk for meningococcal disease among MSM

Questions?